cjc-1295 stack: Frequently asked questions

Continue the protocol and measure body composition through DEXA or bioimpedance instead. AOD-9604's preferential visceral fat targeting means intra-abdominal fat reduces before subcutaneous deposits. This shifts waist-to-hip ratio and metabolic markers (fasting insulin, inflammatory cytokines) without producing dramatic scale changes. Research models consistently show 4-6 week lag between visceral fat reduction and visible peripheral fat loss. If waist circumference decreases but bodyweight stays flat, the protocol is working. Muscle retention from CJC-1295's GH amplification offsets fat loss on the scale.

This is expected. CJC-1295 amplifies GH pulses, which elevates ghrelin (the hunger hormone) as a secondary effect. Structure meals around high-satiety foods (lean protein at 1.6-2.2 g/kg bodyweight, fibrous vegetables, resistant starch) and consider splitting daily calories into 4-5 smaller meals rather than 2-3 larger ones. The appetite increase doesn't negate fat loss if total caloric intake stays in deficit. Some research models pair CJC-1295 with GLP-1 analogs to offset ghrelin elevation, but this adds complexity and cost.

Rotate injection sites across abdomen, thighs, and deltoids to prevent localized irritation. Subcutaneous peptide administration can trigger mild inflammatory response at the injection site. Redness, slight swelling, transient warmth. Especially with daily AOD-9604 dosing. This is typically histamine-mediated and resolves within 2-4 hours. If reactions persist beyond 6 hours or involve spreading erythema, the peptide may be contaminated or improperly reconstituted. Bacteriostatic water is required for multi-dose vials. Sterile water alone doesn't prevent bacterial growth after the first draw.

Administer the missed dose as soon as you remember, then continue your regular schedule. BPC-157's 4-hour half-life means missing one dose creates a 4–8 hour gap in angiogenic signaling, but the cumulative tissue repair effect is what matters over 8–12 weeks. Missing a single dose won't derail the protocol. Missing three or more doses per week will. If you're running twice-daily BPC-157 and consistently miss the second daily dose, drop to once-daily dosing at a higher concentration (500mcg instead of 250mcg twice) rather than maintaining an inconsistent twice-daily schedule.

Don't. Administering BPC-157 and CJC-1295 simultaneously wastes the temporal synergy between them. CJC-1295's mechanism is to raise systemic IGF-1 over 24–48 hours. If you inject BPC-157 at the same moment, its angiogenic effects peak before IGF-1 has risen meaningfully. Stagger the peptides: CJC-1295 first (Monday and Thursday), then daily BPC-157 starting 24–48 hours after the first CJC-1295 dose. That schedule ensures elevated IGF-1 is present when BPC-157 creates new vascular structures requiring collagen support.

Pain reduction is subjective and not the primary marker of tissue repair. BPC-157's angiogenic mechanism creates vascular scaffolding first. Collagen deposition and cross-linking follow weeks later. Some injury types (ligament tears, chronic tendinopathy) show delayed symptomatic improvement because the new tissue must reach load-bearing capacity before pain resolves. If you're three weeks into the BPC-157 CJC-1295 stack with no subjective improvement, verify your dosing schedule (CJC-1295 twice weekly, BPC-157 daily), confirm injection sites are within 2–3 inches of the injury, and continue the protocol to at least week 8 before concluding it's ineffective.